April 17 (Reuters) - Mayne Pharma Group Ltd MYX.AX:
SOL-GEL AND MAYNE PHARMA ANNOUNCE THE PURCHASE OF EPSOLAY® AND TWYNEO® IN THE U.S.
SOL-GEL- TO RECEIVE $16 MILLION DURING 2025
SOL-GEL- SGT-610 PHASE III TRIAL TOP-LINE RESULTS EXPECTED Q4 2026
Source text: ID:nGNX9BXqdP
Further company coverage: MYX.AX
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.